REMEDIUM

The article examines the regional retail sector features of the pharmaceutical market through the example of 35 constituent entities of the Russian Federation, which form seven federal districts. The authors present the quantitative and qualitative characteristics of regional pharmaceutical markets, accessibility index of various socially important types of pharmaceutical asistance to the population (extemporaneous manufacture of dosage forms, dispensing narcotic drugs and psychotropic substances listed in Schedule II and III of Decree of the Government of the Russian Federation No. 681 of June 30, 1998, as well as participation in the pharmaceutical benefit schemes for population privileged groups at the federal and regional levels). It was established that the pharmaceutical market in most of the constituent entities of the Russian Federation is concentrated. The pharmacy organizations in the public sector are the echelon, which bears the main burden of providing the socially significant types of medical care for population, while the public sector accounts for 11.3% of the total number of pharmacy organizations.

24-26 сентября 2019 года в Екатеринбурге под эгидой Российского кардиологического общества (РКО) состоялся Российский национальный конгресс кардиологов. В работе конгресса также принимали участие представители более 10 стран мира: России, Бельгии, Великобритании, Германии, Греции, Израиля, Испании, Италии, Норвегии, США, Турции и Финляндии. В рамках конгресса обсуждались вопросы, касающиеся кардиологии, детской кардиологии, клинической фармакологии, скорой медицинской помощи, гериатрии и др. О конгрессе и роли РКО в решении вопросов, стоящих перед современной наукой, мы беседовали с президентом РКО, гендиректором ФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова», академиком РАН, д.м.н., профессором Евгением Владимировичем Шляхто.

The rhythm of modern life, stresses in the megalopolis environment, hectic working climate are triggers for the development of a variety of neuropsychiatry diseases, including anxiety disorders. Such disorders are not always easy to deal with on your own. In this regard, the choice of optimal pharmacotherapy to manage anxiety disorders is an extremely important task.

За последние годы в России достигнуты заметные положительные сдвиги в сфере лекарственного обеспечения населения, но тема доступности фармакотерапии, особенно инновационной, не теряет своей актуальности. Охарактеризовать сегодняшнюю ситуацию и рассказать о путях ее улучшения и возможных перспективах для российских пациентов мы попросили Василия РЯЖЕНОВА, заведующего кафедрой регуляторных отношений в области обращения ЛС и медицинских изделий Первого МГМУ им. И.М. Оеченова, руководителя центра стратегических исследований в здравоохранении «Качественные медицинские технологии», кандидата фармацевтических наук.

Improving the drug supply for children is one of the priority areas of the development of the Russian healthcare service. The article presents a multi-vector marketing analysis of the national paediatric antibacterials market. The objects of the research included the state register of medicinal products and data from DSM Group marketing agency. It was found that a significant (45%) share of medicinal products (MP) of J01 Group Antibacterials for systemic use, which is formed mainly by beta-lactam products and fluoroquinolones, is provided by the foreign manufacturers. At the same time, the medicinal products in the form of tablets (33%) and powders for preparation of solution for injection (26%) account for the maximum share in the assortment profile. Analysis of the proposal with a breakdown into age restrictions showed that only 24% of the assortment of authorized medicinal products are allowed to use for children aged less than 3 years old. It has been shown that the reproduced MPs currently cover 76.3 and 90.9% of the antibacterials sales pattern in value and physical terms, respectively. At the same time, the renewal index of J01 Antibacterials for systemic use was 2% over the past 5 years. Assessment of the assortment using the multidimensional method of Boston Consulting Group showed that 70% of items within the studied category of drugs are characterized by insignificant investment attractiveness, which is largely determined by the risks of product life cycle reduction in the settings of the development of bacterial resistance. The main parameters and characteristics of the assortment of J01 Antibacterials for systemic use market demonstrate the prospects for expanding the assortment portfolio of the Russian manufacturers due to drugs in the form of children's dosage forms that meet modern pharmacotherapy concepts in paediatrics.

Варикозная болезнь нижних конечностей, являющаяся наиболее частой причиной хронической венозной недостаточности (ХВН), - серьезная клиническая проблема, от решения которой зависит качество жизни значительного числа россиян, прежде всего старшего возраста. О главных факторах риска, приводящих к развитию заболевания, профилактических мероприятиях и специфике лечения мы решили поговорить с Вадимом БОГАЧЕВЫМ, руководителем курса амбулаторной хирургии и стационарзамещающих технологий, профессором кафедры факультетской хирургии №2 РНИМУ им. Н.И. Пирогова, научным руководителем Первого флебологического центра, лауреатом премии правительства РФ в области науки и техники.

The article presents the experience of the experiment conducted in Moscow in 1994-1998 on the ordering of payment for medicines on preferential prescriptions, shows its relevance. Analysis of the results of the experiment allowed to show what challenges it had to face and what is very important, how this experiment can be extrapolated to the realities of today.

Analysis of the Russian implants market has been conducted based on data on public procurement of osteosynthesis devices, and the export-import transaction database of the official customs statistics. In the article, the term «osteosynthesis devices» is used to indicate the medical devices of this type. The purchase of such devices is most important to meet the needs of the public health system. The total consumption of osteosynthesis implants in value terms amounted to about RUB 4.530 bil. in 2018. In general, the consumption has shown positive dynamics, since 2015. The increase in purchases accounted for more than 66% in 2018 compared to 2015. The analysis of the osteosynthesis implants consumption pattern based on the results for 2018 showed that the main share was accounted for by bone implants - 43.40%. The manufacturers of the Asian group - 33% and Locals - 24% demonstrated outperforming growth rates (exceeding the general dynamics of consumption in value terms) over the period from 2015 to 2018. The increase in the supplies of EU&US group manufacturers by 12% is below the market average figures. The analysis of osteosynthesis implant supplies pattern of the regional groups based on the results for 2018 showed that the main share is accounted for by the products from the leading world and European brands - 44.20% or RUB 2.002 bil. A significant share in the total supplies is accounted for by the implants of the Russian manufacturers - 35.26% or RUB 1.597 bil. The leading brands face stiff competition from the local companies in the osteosynthesis implants market.

Тенденции современного российского фармрынка, происходящие на нем процессы и перспективы развития обсудили участники аналитической панели XI Международной конференции «Что происходит на фармрынке». Мероприятие состоялось в начале октября в рамках саммита Pharmastrategies-2020.